Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 2 Uterine Cervical Dysplasia 1 Tongue Neoplasms 1 Stomach Neoplasms 1 Squamous Intraepithelial Lesions 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Paranasal Sinus Neoplasms 1 Oropharyngeal Neoplasms 1 Nasopharyngeal Neoplasms 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

HhAntag691 25 Imiquimod 12 Biopsy 12 sonidegib 11 Aminolevulinic Acid 9 cemiplimab 8 Photochemotherapy 8 Nivolumab 8 methyl 5-aminolevulinate 7 Mohs Surgery 7 1-phenyl-3,3-dimethyltriazene 7 Tomography, Optical Coherence 6 Surgical Procedures, Operative 6 Specimen Handling 5 Radiotherapy 5 Itraconazole 5 pembrolizumab 4 daromun 4 Microscopy, Confocal 4 Magnetic Resonance Spectroscopy 4 Ipilimumab 4 Curettage 4 Standard of Care 3 Niacinamide 3 IPI-926 3 CTLA-4 Antigen 3 3-ingenyl angelate 3 tazarotene 2 talimogene laherparepvec 2 relatlimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Basal Cell × Chemoprevention × Clear all

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡